Allarity Therapeutics, Inc. - $ALLR STOCK NEWS

Allarity Therapeutics, a clinical-stage pharmaceutical company, exceeds Nasdaq's minimum equity requirement of $2.5 million, seeking formal confirmation of compliance. The company plans to withdraw Form S-1 submitted to the SEC, reflecting improved equity status and focusing on advancing stenoparib for ovarian cancer treatment.

Allarity Therapeutics, Inc. announced the early discontinuation of its Phase 2 trial of stenoparib, a PARP inhibitor, for advanced ovarian cancer. The trial showed clear clinical benefit, prompting the company to halt enrollment and focus on a follow-on trial for FDA submission. The patients were pre-screened using Allarity's companion diagnostic for personalized treatment. CEO Thomas Jensen emphasized the substantial positive outcomes and the potential of stenoparib in heavily pre-treated patients.

Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company, regained compliance with Nasdaq's minimum bid price requirement, maintaining a closing bid price above $1.00 per share for over ten consecutive trading days. CEO Thomas Jensen expressed optimism about the clinical potential of their lead asset in advanced ovarian cancer and their commitment to developing new treatment options.

Allarity Therapeutics, a clinical-stage pharmaceutical company, has received an extension until May 14, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(1). The company presented a strategic plan to the Nasdaq Hearings Panel, focusing on cost reduction, capital raising, and operational efficiency. Allarity implemented a 1-for-20 reverse stock split and reduced monthly operational expenditures to $400,000. Negotiations with stakeholders aim to adjust terms for future capital raising. The company is actively raising new equity to meet the $2,500,000 equity requirement by the target date.

Allarity Therapeutics, Inc. announces a 1-for-20 reverse stock split to comply with Nasdaq's bid price requirement and operational benefits.

Allarity Therapeutics, Inc. announces a strategic pivot to focus on advancing stenoparib in advanced recurrent ovarian cancer, based on promising Phase 2 trial data. The company shifts resources to accelerate stenoparib development, deprioritizing IXEMPRA® and dovitinib. The decision aims to address an unmet medical need, reduce costs, and align with the growing PARP inhibitor market.

Allarity Therapeutics, Inc. (NASDAQ: ALLR) receives a formal extension until April 24, 2024, to regain compliance under Nasdaq Listing Rules. The company has presented a strategic plan to address compliance deficiencies, focusing on achieving a stockholders' equity of at least $2.5 million and a minimum bid price of $1.00 per share for 10 consecutive business days. The plan includes cost reduction, liability conversion, and seeking additional capital to strengthen financial position and operational efficiency.

Allarity Therapeutics, Inc. reported significant advancements in personalized cancer treatments in 2023, with a focus on stenoparib for advanced ovarian cancer. The company reduced net loss from operations by 50% and net loss by 26%. Key highlights include the appointment of Thomas Jensen as Interim CEO, data showing clinical benefit in ovarian cancer trials, and engagement of Jeremy Graff, Ph.D. as an Executive Advisor. Anticipated milestones for 2024 include the disclosure of interim data from the Phase 2 clinical trial of stenoparib.

Allarity Therapeutics, Inc. has been invited to present at Biomarkers 2024, showcasing their innovative work on the Drug Response Predictor (DRP®) companion diagnostics platform. The CEO, Thomas Jensen, will discuss the application of DRP® in an ongoing ovarian cancer trial, aiming to identify patients likely to benefit from treatment. The company's presentation will shed light on their cutting-edge personalized cancer treatment approach.